Issue navigation
Volume 5, Issue Supplement_5, December 2023
Abstracts to the 41st Annual Meeting of the Japan Society for Neuro-Oncology
ABSTRACTS
ED-1 PITUITARY TUMORS IN 5TH WHO CLASSIFICATION 2022: WHAT DO YOU MEAN BY PITNET?
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v1, https://doi.org/10.1093/noajnl/vdad141.001
10000-SPE-1 STEM CELL-BASED GENE THERAPY FOR MALIGNANT GLIOMA USING GENOME-EDITED HUMAN INDUCED PLURIPOTENT STEM CELLS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v1, https://doi.org/10.1093/noajnl/vdad141.002
10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v1, https://doi.org/10.1093/noajnl/vdad141.003
10005-ANGI-1 REGULATION OF ALTERNATIVE ANGIOGENIC FACTORS IN BEVACIZUMAB THERAPY FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v1–v2, https://doi.org/10.1093/noajnl/vdad141.004
10006-PEDT-1 PEDIATRIC LOWER GRADE GLIOMA SURGERY IN THE ERA OF GENOMIC MEDICINE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v2, https://doi.org/10.1093/noajnl/vdad141.005
10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v2, https://doi.org/10.1093/noajnl/vdad141.006
10008-CBMS-1 THE NOVEL MDM4 INHIBITOR CEP-1347 ACTIVATES THE P53 PATHWAY AND BLOCKS MALIGNANT MENINGIOMA GROWTH IN VITRO AND IN VIVO
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v2, https://doi.org/10.1093/noajnl/vdad141.007
10014-CBMS-2 CONCURRENT TARGETING OF MDM4 AND MDM2 USING CEP-1347 AS AN EFFECTIVE THERAPEUTIC STRATEGY FOR P53 WILD-TYPE MALIGNANT BRAIN TUMORS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v2–v3, https://doi.org/10.1093/noajnl/vdad141.008
10015-NI-1 PREDICTION OF MGMT PROMOTOR METHYLATION STATUS IN GLIOBLASTOMA BY CONTRAST-ENHANCED T1-WEIGHTED IMAGE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v3, https://doi.org/10.1093/noajnl/vdad141.009
10018-COT-4 COMPARATIVE VOLUMETRIC ANALYSES FOLLOWING BEVACIZUMAB THERAPY FOR A PATIENT WITH CO- INCIDENCE OF GLIOBLASTOMA, MENINGIOM
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v3, https://doi.org/10.1093/noajnl/vdad141.010
10020-ML-1 SENTINEL LESION PRECEDING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v3, https://doi.org/10.1093/noajnl/vdad141.011
10021-IMT-1 A ROLE OF DENDRITIC CELL IMMUNOTHERAPY AS A MODALITY IN MULTIDISCIPLINARY THERAPY FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v3–v4, https://doi.org/10.1093/noajnl/vdad141.012
10022-MET-2 CLINICAL FEATURES OF RENAL CELL CARCINOMA BRAIN METASTASES COMPARED WITH OTHER CARCINOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v4, https://doi.org/10.1093/noajnl/vdad141.013
10024-CO-1 A MULTICENTER PERFORMANCE COMPARISON STUDY OF AN IDH STATUS PREDICTION MODEL USING THE VISUAL TRANSFORMER MODEL
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v4, https://doi.org/10.1093/noajnl/vdad141.014
10025-MPC-3 DIFFERENCE AMONG GENERATIONS IN PATIENTS WITH HISTONE H3-MUTATED GLIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v4, https://doi.org/10.1093/noajnl/vdad141.015
10027-CBMS-3 POSTOPERATIVE EPILEPTOGENICITY IN GLIOBLASTOMA ARE ACHIEVED AS THE RESULT OF INTERACTIVE FLUCTUATIONS OF GLUTAMATE AND STEM CELL MARKER
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v4–v5, https://doi.org/10.1093/noajnl/vdad141.016
10031-GGE-2 GENOMIC ANALYSIS OF MENINGIOMA USING GENE PANEL TESTING
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v5, https://doi.org/10.1093/noajnl/vdad141.017
10033-IM-2 IDENTIFICATION OF THERAPEUTIC TARGET ANTIGENS USING PATIENT DERIVED GLIOBLASTOMA AND THEIR APPLICATION TO CAR-T THERAPY
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v5, https://doi.org/10.1093/noajnl/vdad141.018
10035-GMC-1 PTPN11 VARIANT MAY BE A PROGNOSTIC INDICATOR OF IDH-WILDTYPE GLIOBLASTOMA IN A COMPREHENSIVE GENOMIC PROFILING COHORT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v5, https://doi.org/10.1093/noajnl/vdad141.019
10036-IM-3 SPATIAL AND GENOMIC ANALYSES FOR THE CONSTRUCTION OF TERTIARY LYMPHOID STRUCTURE IN GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v5–v6, https://doi.org/10.1093/noajnl/vdad141.020
10037-SPE-3 APPROACH TO SAFE AND RELIABLE BRAIN TUMOR SURGERY APPLYING INTRAOPERATIVE GAMMA OSCILLATION REGULARITY ANALYSIS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v6, https://doi.org/10.1093/noajnl/vdad141.021
10038-ANGI-2 NEW ANTI-ANGIOGENIC THERAPY WITH THE ANTI-DEPRESSANT TOWARD TUMOR DERIVED ENDOTHELIAL CELLS (TDECS)
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v6, https://doi.org/10.1093/noajnl/vdad141.022
10045-MET-4 CEREBROSPINAL FLUID DIVERSION FOLLOWED BY SYSTEMIC THERAPY FOR LEPTOMENINGEAL METASTASIS-RELATED HYDROCEPHALUS IN PATIENTS WITH SOLID CANCER: ASSESSMENT WITH CLASSIFICATION OF EANO-ESMO CLINICAL PRACTICE GUIDELINE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v6, https://doi.org/10.1093/noajnl/vdad141.023
10048-CO-2 CAN NATURAL LANGUAGE PROCESSING AI BE AN APPROPRIATE “ADVISER” FOR BRAIN TUMOR PATIENTS? CLINICAL APPLICATION AND ISSUES ON CHATGPT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v6–v7, https://doi.org/10.1093/noajnl/vdad141.024
10049-GGE-3 CHARACTERISTICS OF CHROMOSOMAL ABERRATIONS IN GLIOMAS AND THEIR IMPACT ON RECURRENCE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v7, https://doi.org/10.1093/noajnl/vdad141.025
10050-TB-1 ADDITIONAL RAS/MAPK PATHWAY ACTIVATION ALLOWS CELLS TO DIFFERENTIATE DURING TUMORIGENESIS.
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v7, https://doi.org/10.1093/noajnl/vdad141.026
10051-CBMS-4 CURCUMIN ANALOG COMPOUND A INHIBITS THE GROWTH OF GLIOBLASTOMA BY INDUCING G2/M PHASE ARREST AND APOPTOSIS AT A LOWER CONCENTRATION THAN CURCUMIN
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v7, https://doi.org/10.1093/noajnl/vdad141.027
10053-MNG-1 STRATIFICATION OF TUMOR VOLUME GROWTH RATE USING RISK FACTORS IN SUPRATENTORIAL MENINGIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v7–v8, https://doi.org/10.1093/noajnl/vdad141.028
10054-STMO-1 5-ALA INTENSITY ANALYSIS OF NON-NEOPLASTIC LESIONS BY IMAGE J
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v8, https://doi.org/10.1093/noajnl/vdad141.029
10060-MET-5 LEPTOMENINGEAL METASTASES FROM HER2 POSITIVE SALIVARY GLAND CARCINOMATREATED WITH CRANIOSPINAL IRRADIATION FOLLOWED BY INTRATHECAL TRASTUZUMAB
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v8, https://doi.org/10.1093/noajnl/vdad141.030
10064-GGE-6 A MULTI-OMIC LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v8, https://doi.org/10.1093/noajnl/vdad141.031
10073-CBMS-6 CURCUMIN ANALOG B EXHIBIT ANTI-TUMOR ACTIVITY AGAINST GLIOBLASTOMAAT LOWER CONCENTRATIONS THAN CURCUMIN
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v8–v9, https://doi.org/10.1093/noajnl/vdad141.032
10074-COT-10 A NEW PREOPERATIVE PREDICTIVE SCORING SYSTEM FOR SUPRATENTORIAL NEWLY DIAGNOSED ISOCITRATE DEHYDROGENASE-WILD TYPE GLIOBLASTOMA TREATED WITH RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v9, https://doi.org/10.1093/noajnl/vdad141.033
10075-CO-3 PREDICTION OF KPS DETERIORATION IN GLIOBLASTOMA USING MULTIMODAL LEARNING WITH PRE- AND POST-OPERATIVE MRI IMAGES AND CLINICAL INFORMATION
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v9, https://doi.org/10.1093/noajnl/vdad141.034
10077-NI-4 POSTOPERATIVE DISAPPEARANCE OF LEPTOMENINGEAL ENHANCEMENT AROUND THE BRAINSTEM IN GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v9, https://doi.org/10.1093/noajnl/vdad141.035
10079-MPC-6 RADIOLOGICAL AND MOLECULAR ANALYSIS OF WHO GRADE 4 BUTTERFLY GLIOMAS WITH A TAILORED SURGICAL APPROACH
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v9, https://doi.org/10.1093/noajnl/vdad141.036
10082-RT-1 LONG-TERM RESULTS OF A BNCT PHASE II CLINICAL TRIAL USING AN ACCELERATOR-BASED NEUTRON SOURCE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v9–v10, https://doi.org/10.1093/noajnl/vdad141.037
10084-TB-2 IN VITRO CHARACTERIZATION OF COMBINATION THERAPY IN GENETICALLY-ENGINEERED MURINE DIFFUSE MIDLINE GLIOMA MODELS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v10, https://doi.org/10.1093/noajnl/vdad141.038
10085-RT-2 TREATMENT RESULTS OF AVAGAMMA THERAPY FOR RECURRENT GLIOBLASTOMA COMBINED WITH GAMMA KNIFE AND BEVACIZUMAB
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v10, https://doi.org/10.1093/noajnl/vdad141.039
10087-GGE-7 THE IMMUNE PROGNOSTIC MODEL FOR GLIOBLASTOMA BASED ON SSGSEA ENRICHMENT SCORE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v10, https://doi.org/10.1093/noajnl/vdad141.040
10089-CO-4 DEVELOPMENT OF A PHYSICIAN SUPPORT SYSTEM FOR ANALYSIS OF GENETIC MUTATIONS IN BRAIN TUMORS AND SELECTION OF CLINICAL TRIALS USING LARGE-SCALE LANGUAGE MODELS (LLMS) WITH RETRIEVER
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v10–v11, https://doi.org/10.1093/noajnl/vdad141.041
10091-COT-12 ELUCIDATING THE PATHOPHYSIOLOGY OF POST-OPERATIVE VENOUS THROMBOEMBOLISM IN IDH-WILDTYPE MALIGNANT GLIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v11, https://doi.org/10.1093/noajnl/vdad141.042
10094-MPC-8 MOLECULAR PATHOLOGICAL ANALYSIS OF RADIATION-INDUCED GLIOBLASTOMA AFTER PEDIATRIC CEREBELLAR MEDULLOBLASTOMA TREATMENT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v11, https://doi.org/10.1093/noajnl/vdad141.043
10097-ACT-6 PHASE 1/2, PROSPECTIVE, INTERNATIONAL MULTI-CENTER STUDY TO ESTABLISH THE SAFETY AND FEASIBILITY OF BLOOD-BRAIN-BARRIER DISRUPTION COMBINED WITH CARBOPLATIN FOR RECURRENT GLIOBLASTOMA; FIRST CLINICAL EXPERIENCE IN JAPAN
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v11, https://doi.org/10.1093/noajnl/vdad141.044
10098-MPC-10 HOW SHOULD WE RESPOND TO REPEATED WHO REVISIONS? IN-HOUSE MOLECULAR DIAGNOSIS SYSTEM BY ADVANCED MEDICAL SYSTEM
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v11–v12, https://doi.org/10.1093/noajnl/vdad141.045
10100-MNG-4 RISK FACTORS FOR POSTOPRATIVE RECURRENCE IN PATIENTS WITH CONVEXITY, PARASAGITTAL AND FALX MENINGIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v12, https://doi.org/10.1093/noajnl/vdad141.046
10103-GMC-7 RETROSPECTIVE ANALYSIS ABOUT BEVACIZUMAB THERAPY FOR 10 YEARS AFTER AUTHORIZATION FOR MALIGNANT GLIOMAS IN OUR DEPARTMENT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v12, https://doi.org/10.1093/noajnl/vdad141.047
10109-COT-13 LONG-TERM FOLLOW-UP OF FLAIR HIGH LESION IN THE BRAIN
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v12, https://doi.org/10.1093/noajnl/vdad141.048
10111-MPC-11 CLINICAL AND MOLECULAR NEUROPATHOLOGICAL FEATURES OF EPITHELIOID GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v12–v13, https://doi.org/10.1093/noajnl/vdad141.049
10114-GMC-10 EXPERIENCE WITH DIFFERENTIAL NTRK2 FUSION GENE DETECTION IN CANCER MULTI-GENE PANEL TESTING
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v13, https://doi.org/10.1093/noajnl/vdad141.050
10115-STMO-4 SURGICAL OUTCOMES OF AWAKE SURGERY FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v13, https://doi.org/10.1093/noajnl/vdad141.051
10119-ACT-9 LONG-TERM USAGE OF TUMOR-TREATING FIELDS THERAPY FOR TREATMENT OF MALIGNANT GLIOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v13, https://doi.org/10.1093/noajnl/vdad141.052
10121-BT-8 CLINICOPATHOLOGICAL ANALYSIS OF CENTRAL NERVOUS SYSTEM GERM CELL TUMORS -387CASES IN THE JCCG COHORT AND THE IGCT CONSORTIUM COHORT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v13–v14, https://doi.org/10.1093/noajnl/vdad141.053
10125-GGE-10 EVALUATION OF MGMT PROMOTER METHYLATION STATUS OF GBM CELL LINE CLONAL POPULATION.
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v14, https://doi.org/10.1093/noajnl/vdad141.054
10126-ACT-10 FACTORS AFFECTING THE PATTERN OF RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v14, https://doi.org/10.1093/noajnl/vdad141.055
10127-COT-15 REGIONAL MEDICAL DISPARITIES AND RESPONSES TO THE INCREASING COMPLEXITY OF GLIOBLASTOMA TREATMENT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v14, https://doi.org/10.1093/noajnl/vdad141.056
10141-GMC-13 MULTIREGIONAL GENOMIC ANALYSIS: A NOVEL APPROACH FOR DETECTING PATHOGENIC DRIVER MUTATION ASSOCIATED WITH MALIGNANT PROGRESSION IN NEUROCUTANEOUS MELANOSIS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v14–v15, https://doi.org/10.1093/noajnl/vdad141.057
10143-COT-16 DIFFUSE BONE MARROW METASTASIS OF HIGH GRADE GLIOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v15, https://doi.org/10.1093/noajnl/vdad141.058
10150-GGE-16 INTRAOPERATIVE INTEGRATED DIAGNOSTIC SYSTEM FOR MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v15, https://doi.org/10.1093/noajnl/vdad141.059
10152-PEDT-5 JAPANESE SUBGROUP ANALYSIS OF A PHASE II TRIAL OF DABRAFENIB PLUS TRAMETINIB (D+T) IN BRAF V600-MUTANT PEDIATRIC LOW-GRADE GLIOMA (PLGG) AND RELAPSED/REFRACTORY (R/R) BRAF V600-MUTANT PEDIATRIC HIGH-GRADE GLIOMA (PHGG)
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v15, https://doi.org/10.1093/noajnl/vdad141.060
10154-PEDT-6 RETROSPECTIVE STUDY OF 12 PEDIATRIC EPENDYMOMAS TREATED AT OUR HOSPITAL
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v15–v16, https://doi.org/10.1093/noajnl/vdad141.061
10157-BOT-1 DISCRIMINATION OF EPENDYMOMA AND MEDULLOBLASTOMA BY RAMAN SPECTROSCOPY
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v16, https://doi.org/10.1093/noajnl/vdad141.062
10159-STMO-7 INTRAOPERATIVE MRI SURGERY FOR POSTERIOR FOSSA LESIONS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v16, https://doi.org/10.1093/noajnl/vdad141.063
10162-STMO-8 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR BRAIN METASTASIS.
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v16, https://doi.org/10.1093/noajnl/vdad141.064
10167-MET-8 CLINICAL CHARACTERISTICS AND TREATMENT STRATEGY OF CANCER CASES PRESENTING WITH CENTRAL NERVOUS SYSTEM SYMPTOMS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v16–v17, https://doi.org/10.1093/noajnl/vdad141.065
10168-BOT-2 ANTITUMOR AROMA THERAPY WITH LEMONGRASS ESSENTIAL OIL FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v17, https://doi.org/10.1093/noajnl/vdad141.066
10170-GMC-14 CRANIOPHARYNGIOMA REFRACTORY TO SURGERY AND RADIOSURGERY SUCCESSFULLY TREATED WITH ENCORAFENIB AND BINIMETINIB: A CASE REPORT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v17, https://doi.org/10.1093/noajnl/vdad141.067
10171-MPC-13 IDH-WILDTYPE LOWER-GRADE ASTROCYTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v17, https://doi.org/10.1093/noajnl/vdad141.068
10172-IM-6 DEVELOPMENT OF CAR-NK CELL THERAPY TARGETING B7H3 AGAINST GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v17, https://doi.org/10.1093/noajnl/vdad141.069
10175-GGE-17 MOLECULAR CHARACTERIZATION OF LOW-GRADE DIFFUSELY INFILTRATIVE TUMOR WITH INI1 DEFICIENCY
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v17–v18, https://doi.org/10.1093/noajnl/vdad141.070
10177-ML-5 HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT FOR RECURRENT CNS LYMPHOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v18, https://doi.org/10.1093/noajnl/vdad141.071
10179-NI-8 CLINICORADIOLOGICAL CHARACTERISTICS OF H3 K27-ALTERED THALAMIC GLIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v18, https://doi.org/10.1093/noajnl/vdad141.072
10181-STMO-9 EFFECT OF INTRAOPERATIVE VENTRICULAR OPENING ON RECURRENCE PATTERNS FOLLOWING BCNU WAFER IMPLANTATION FOR NEWLY DIAGNOSED MALIGNANT GLIOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v18, https://doi.org/10.1093/noajnl/vdad141.073
10184-BT-14 CLINICAL FEATURE OF HEMISPHERIC GLIOMA WITH H3F3A, PEDIATRIC-TYPE HIGH GRADE GLIOMA, H3 K27-ALTERED, NEC AND DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, CNS WHO GRADE 4
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v18–v19, https://doi.org/10.1093/noajnl/vdad141.074
10190-MPC-14 ANALYSIS OF GENETIC ABNORMALITIES IN TERTP-WILDTYPE MOLECULAR GBM
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v19, https://doi.org/10.1093/noajnl/vdad141.075
10195-MET-11 THE PREDICTIVE FACTORS OF EFFICACY OF PEMBROLIZUMAB IN BRAIN METASTASES OF LUNG CANER
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v19, https://doi.org/10.1093/noajnl/vdad141.076
10199-SPDR-2 PERSONALIZED SYNTHETIC LETHALITY INDUCED BY TARGETING ATR-CHK1 IN MEDULLOBLASTOMAS IDENTIFIED BY IMPLEMENTATION OF SLFN11 IMMUNOHISTOCHEMISTRY
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v19, https://doi.org/10.1093/noajnl/vdad141.077
10203-ML-6 TIRABRUTINIB FOR PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTE RETROSPECTIVE ANALYSIS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v19–v20, https://doi.org/10.1093/noajnl/vdad141.078
10204-NQPC-7 EFFECTIVENESS AND PROBLEM OF CONVALESCENT REHABILITATION FOR INDEPENDENT LIVING IN THEIR HOUSE OF PATIENTS WITH BRAIN TUMOR
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v20, https://doi.org/10.1093/noajnl/vdad141.079
10205-TB-8 ABSENCE OF RNF213 IN MEDULLOBLASTOMA INDUCES STARVATION RESISTANCE VIA GAS6 AND RESULTS IN TUMOR PROGRESSION
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v20, https://doi.org/10.1093/noajnl/vdad141.080
10206-GGE-21 MOLECULAR LANDSCAPE AND TUMOR EVOLUTION IN ASTROBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v20–v21, https://doi.org/10.1093/noajnl/vdad141.081
10210-STMO-13 CLINICAL AND GENETIC ANALYSIS OF ADULT THALAMIC GLIOMAS - SIGNIFICANCE OF H3K27M AND TERT MUTATIONS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v21, https://doi.org/10.1093/noajnl/vdad141.082
10213-GMC-16 A DECADE REVIEW: BEVACIZUMAB'S IMPACT ON GLIOBLASTOMA TREATMENT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v21, https://doi.org/10.1093/noajnl/vdad141.083
10214-COT-24 A RARE CLINICAL CASE OF LUMBAR METASTASIS FROM GLIOSARCOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v21, https://doi.org/10.1093/noajnl/vdad141.084
10215-ML-7 CLINICAL OUTCOME OF TIRABRUTINIB IN PCNSL REFRACTORY TO R-MPV THERAPY
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v21–v22, https://doi.org/10.1093/noajnl/vdad141.085
10220-NI-9 PREDICTION OF AN EFFECT OF ELIMINATING HIGH INTENSITY AREAS ON FLAIR IMAGING AFTER ONE-SHOT BEVACIZUMAB FOR GLIOBLASTOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v22, https://doi.org/10.1093/noajnl/vdad141.086
10221-ML-11 A CASE OF PRIMARY CENTRAL NERVOUS SYSTEM ADULT T CELL LEUKEMIA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v22, https://doi.org/10.1093/noajnl/vdad141.087
10223-ML-12 SYSTEMIC RELAPSE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v22, https://doi.org/10.1093/noajnl/vdad141.088
10233-GMC-17 CLINICAL SIGNIFICANCE OF GENETIC ANALYSIS FOR GLIOMA CASES IN OUR INSTITUTE
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v22, https://doi.org/10.1093/noajnl/vdad141.089
10235-TB-9 TRANSLATIONAL RESEARCH OF BORON NEUTRON CAPTURE THERAPY FOR SPINAL CORD AND SPINE TUMOR IN ANIMAL MODELS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v22–v23, https://doi.org/10.1093/noajnl/vdad141.090
10236-NI-11 IMAGING FEATURES AND CONSIDERATION OF PROGRESSION PATTERN OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v23, https://doi.org/10.1093/noajnl/vdad141.091
10243-IMT-3 LONG-TERM OUTCOME OF A COCKTAIL WILMS' TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE AGAINST RECURRENT MALIGNANT GLIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v23, https://doi.org/10.1093/noajnl/vdad141.092
10247-ET-8 HHYPOXIA-TARGETING RADIOPHARMACEUTICAL 64CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA PATIENT-DERIVED XENOGRAFT MODEL
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v23, https://doi.org/10.1093/noajnl/vdad141.093
10249-PEDT-8 CURRENT STATUS AND ISSUES OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v23–v24, https://doi.org/10.1093/noajnl/vdad141.094
10252-COT-27 TWO CASES OF OVARIAN HYPERSTIMULATION SYNDROME IN A YOUNG FEMALE PATIENTS WITH GLIOMA WHO UNDERWENT OOCYTE CRYOPRESERVATION.
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v24, https://doi.org/10.1093/noajnl/vdad141.095
10255-BOT-5 EXOSOMAL MIRNAS RELEASED FROM GLIOBLASTOMA CELLS AFTER BNCT TARGET CELL PROLIFERATION AND SURVIVAL SIGNALS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v24, https://doi.org/10.1093/noajnl/vdad141.096
10259-NQPC-9 CONTROVERSY ON INVASIVE AIRWAY MANAGEMENT IN PATIENTS WITH BRAIN STEM MALIGNANT GLIOMA.
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v24, https://doi.org/10.1093/noajnl/vdad141.097
10264-NQPC-10 ACTIVITY RECORD OF THE JAPAN BRAIN TUMOR ALLIANCE, AND THE NEEDS OF BRAIN TUMOR PATIENTS AND FAMILIES
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v24–v25, https://doi.org/10.1093/noajnl/vdad141.098
10268-NI-13 T2-FLAIR MISMATCH SIGN CORRELATES WITH11C-METHIONINE UPTAKE IN LOWER-GRADE DIFFUSE GLIOMAS
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v25, https://doi.org/10.1093/noajnl/vdad141.099
10269-ET-10 ARRAYS FOR DELIVERING TUMOR TREATING FIELDS (TTFIELDS) TO THE MOUSE HEAD
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Page v25, https://doi.org/10.1093/noajnl/vdad141.100
AUTHOR INDEX
Author Index
Neuro-Oncology Advances, Volume 5, Issue Supplement_5, December 2023, Pages v26–v29, https://doi.org/10.1093/noajnl/vdad141.101
